Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 02, 2025

Article

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Mayo Clinic Researchers Identify a Measurable Genetic Mutation as a Significant Predictor of Metastasis and Survival in Pancreatic Cancer

March 31, 2025

Article

A Mayo Clinic study showed that KRAS circulating tumor DNA strongly indicates a higher risk of pancreatic cancer spread and worse survival rates.

Five Under 5: Top Oncology Videos for the Week of 3/23

March 30, 2025

Article

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Dr Tyson on Factors Influencing the Selection of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

March 25, 2025

Video

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23, 2025

Article

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Brentuximab Vedotin Combo Adds Another Targeted Option Beyond CD19/CD20 in R/R LBCL

March 19, 2025

Article

Grzegorz S. Nowakowski, MD, discusses the FDA approval of brentuximab vedotin plus lenalidomide and rituximab for relapsed/refractory LBCL.

Mayo Clinic Researchers Identify Proteins Linked to Immunotherapy Resistance in Metastatic Colorectal Cancer

March 14, 2025

Article

A discovery by researchers from Mayo Clinic may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer.

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

March 13, 2025

Video

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in relapsed/refractory LBCL.

Advanced Therapies and Innovative Options for Prostate Cancer Care

February 13, 2025

Article

Multidisciplinary treatment addresses all facets of patient health, resulting in personalized prostate cancer treatment plans that optimize outcomes.

Other Key Follicular Lymphoma Data From ASH 2024

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.

Data for Mosunetuzumab in Newly Diagnosed Follicular Lymphoma

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss data for mosunetuzumab in newly diagnosed follicular lymphoma.

2-Year Follow-Up Data for Liso-Cel in R/R Follicular Lymphoma

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss 2-year follow-up data for liso-cel in relapsed/refractory follicular lymphoma.

CD19 Expression Loss and Tafasitamab in R/R DLBCL

February 04, 2025

Video

Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss CD19 expression and the use of tafasitamab in relapsed/refractory DLBCL.